Proscia Aperture

Proscia Aperture™ is a real-world data and patient insights platform designed for biopharma and life sciences companies seeking to accelerate precision drug development and generate real-world evidence for market access strategies. Powered by Proscia's global network of diagnostic laboratories reviewing more than 8 million cases annually on the Concentriq® enterprise pathology platform, Aperture surfaces patient insights at the moment of earliest diagnosis — days to weeks before EHR or genomics-based approaches — enabling sponsors to act before therapeutic windows close.

Aperture transforms routine pathology diagnoses into actionable intelligence by linking AI-enriched tissue images, AI-derived biomarkers, molecular results, clinical data, and genomic data into comprehensive, multi-dimensional patient profiles. The platform draws from a multimodal database of 12 million or more digitized whole slide images matched to clinical and genomic records, processing more than 32,000 diagnoses daily across a geographically and demographically diverse global network of academic medical centers, healthcare systems, and reference laboratories.

Core Capabilities

• Real-time, point-of-diagnosis patient identification — surfacing eligible patients within moments of diagnosis, ahead of EHR or genomics-dependent platforms.
• Access to a growing global diagnostic network delivering 8 million or more diagnoses annually and a database of 12 million or more digitized slides.
• Multi-dimensional, AI-enriched patient profiles combining tissue images, AI-derived biomarkers, molecular results, and clinical and genomic data.
• AI-powered biomarker detection, image feature extraction, and diagnostic metadata analysis running on the Concentriq platform.
• Structured query interface enabling sponsors to define complex inclusion and exclusion criteria for precise cohort matching, including rare or hard-to-find patient populations.
• Tokenized linkage to longitudinal records, EHRs, and genomics data to provide complete diagnostic context.
• Geographically and demographically diverse data sourcing to improve trial representation and meet regulatory expectations for real-world population diversity.

Value Across the Precision Medicine Lifecycle

• Discovery and Translational Research: Monitor biomarker prevalence across diverse real-world populations to validate biomarker strategies before major trial investments; leverage the multimodal database to identify novel biomarkers, drug targets, and AI-based companion diagnostics; discover overlooked or rare indications faster by monitoring diagnosis trends.
• Clinical Development: Model disease and biomarker prevalence to predict enrollment feasibility and refine trial criteria; identify eligible patients before therapeutic windows close; activate the most productive trial sites and maximize enrollment efficiency by tracking real-time diagnosis volume and patient flow.
• Commercialization and Market Access: Use point-of-diagnosis data to identify treatment delays earlier in the care journey and increase patient access to targeted therapies; generate real-world evidence from diverse care settings to demonstrate effectiveness and patient population characteristics; continuously monitor drug or companion diagnostic performance to discover indication expansion opportunities.

AI's Role in Aperture

• AI models on Concentriq power biomarker detection, image feature extraction, and diagnostic metadata analysis.
• Quantified tissue morphology, visual phenotype detection, and feature extraction results are all queryable within the platform.
• AI rapidly sifts through tissue images, biomarkers, molecular results, and clinical records to match patients with the right trials and treatments in real time.
• AI-enriched data supports regulatory filings, companion diagnostic development, label expansions, and payer discussions.

Regulatory and Market Access Support

• Aperture's AI-enriched diagnostic data and biomarker monitoring insights can be used to generate regulatory-grade real-world evidence.
• Sponsors use this data to strengthen FDA and EMA submissions, support label expansions, inform payer negotiations, and accelerate market access for precision therapies.
• Evidence is delivered via Concentriq, the same enterprise platform supporting 16 of the top 20 pharmaceutical companies across discovery, development, and commercialization.

Aperture is available today for select Proscia Concentriq® customers. Anatomic pathology laboratories that have adopted digital pathology through Concentriq automatically gain access to the opportunities Aperture delivers. The platform integrates directly into existing diagnostic workflows without requiring any workflow changes at the lab level, enabling academic medical centers, healthcare systems, and reference laboratories to play a larger role in advancing novel therapies while tapping into new opportunities for business growth.